Background
Phase II, open-label RCT. 417 patients with HER2+ locally advanced, inflammatory, or early breast cancer randomized to 4 neoadjuvant arms. Primary objective: establish efficacy of dual HER2 blockade (pertuzumab + trastuzumab) in neoadjuvant setting. Pertuzumab targets HER2 dimerization domain, complementing trastuzumab's domain IV binding.
Interventions and follow up
Arm A: Pertuzumab + trastuzumab + docetaxel 75mg/m² q3wk × 4 cycle
Arm B: Trastuzumab + docetaxel × 4 cycles (control)
Arm C: Pertuzumab + trastuzumab (no chemotherapy) × 4 cycle
Arm D: Pertuzumab + docetaxel × 4 cycle
Primary endpoint: pCR (ypT0/is ypN0) in Arm A vs B
mFollow up: 5 years (DFS analysis)
Arm B: Trastuzumab + docetaxel × 4 cycles (control)
Arm C: Pertuzumab + trastuzumab (no chemotherapy) × 4 cycle
Arm D: Pertuzumab + docetaxel × 4 cycle
Primary endpoint: pCR (ypT0/is ypN0) in Arm A vs B
mFollow up: 5 years (DFS analysis)
Results
pCR (Arm A vs B): 45.8% vs 29.0%, P=.0141
pCR (Arm C: pertuzumab+trastuzumab without chemo): 16.8%
pCR (Arm D: pertuzumab+docetaxel): 24.0%
5-yr PFS: 86% (Arm A) vs 81% (Arm B) — directionally favorable
pCR (Arm C: pertuzumab+trastuzumab without chemo): 16.8%
pCR (Arm D: pertuzumab+docetaxel): 24.0%
5-yr PFS: 86% (Arm A) vs 81% (Arm B) — directionally favorable
Adverse events
Hematologic: grade ≥3 febrile neutropenia Arm A 13.0% vs Arm B 7.9%
GI: grade ≥3 diarrhea 5.6% (Arm A)
Cardiac: LVEF decline ≥10% to <50% 4.5% (Arm A) — manageable; LVEF monitoring required
GI: grade ≥3 diarrhea 5.6% (Arm A)
Cardiac: LVEF decline ≥10% to <50% 4.5% (Arm A) — manageable; LVEF monitoring required
Conclusions
Adding pertuzumab to trastuzumab + docetaxel significantly increased pCR rate in HER2+ early BC. NeoSphere provided the pivotal pCR data supporting pertuzumab's accelerated FDA approval in neoadjuvant HER2+ BC — a landmark in biomarker-based accelerated approval using pCR as a surrogate endpoint.
Key Limitations
Key Limitations: Phase II trial with pCR as primary endpoint — not powered for definitive DFS/OS conclusions. pCR as a surrogate for long-term outcome remains controversial (CTNeoBC meta-analysis showed correlation at population but not individual patient level). Docetaxel-only backbone (no anthracycline) was used — current practice typically incorporates anthracycline-taxane chemotherapy in high-risk patients. Long-term DFS benefit directionally favorable but statistically underpowered.
Clinical Context
NeoSphere provided the pCR evidence leading to FDA accelerated approval of pertuzumab in neoadjuvant HER2+ BC (2013). The PEONY trial later confirmed similar pCR benefit in Asian populations. Pertuzumab + trastuzumab + chemotherapy (TCH-P or AC-THP) is now standard neoadjuvant therapy for stage II–III HER2+ BC per ASCO and ESMO guidance. ESMO-MCBS score: N/A (neoadjuvant pCR endpoint; not a DFS/OS trial).
References